Item 8.01 Other Events.

On January 19, 2022, VYNE Therapeutics Inc. (the "Company") issued a press release entitled "VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

In addition, the Company updated its investor presentation to include a slide (slide 13) detailing the Phase 1b data. The updated investor presentation can be found in the "Events & Presentations" section of the Company's website, https://vynetherapeutics.com/investors-media/events_presentations/.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

The following exhibit is being filed herewith.





Exhibit No.  Description

  99.1         Press Release, dated January 19, 2022.

             Cover Page Interactive Data File (embedded within the Inline XBRL
104          document)

© Edgar Online, source Glimpses